2013 Annual revenues


Annual revenues as of December 31, 2013

<table>
<thead>
<tr>
<th>In €</th>
<th>31/12/2013 (12 months)</th>
<th>31/12/2012 (12 months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>190,068</td>
<td>74,153</td>
</tr>
<tr>
<td>Of which:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>License</td>
<td>185,030</td>
<td>74,153</td>
</tr>
<tr>
<td>Services</td>
<td>5,038</td>
<td>-</td>
</tr>
</tbody>
</table>

Revenues for the 4th quarter of 2013

<table>
<thead>
<tr>
<th>In €</th>
<th>Q4 2013</th>
<th>Q3 2013</th>
<th>Q2 2013</th>
<th>Q1 2013</th>
<th>Q4 2012*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>48,667</td>
<td>46,351</td>
<td>48,569</td>
<td>46,481</td>
<td>46,409</td>
</tr>
<tr>
<td>Of which:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>License</td>
<td>46,351</td>
<td>46,351</td>
<td>45,847</td>
<td>46,481</td>
<td>46,409</td>
</tr>
<tr>
<td>Services</td>
<td>2,316</td>
<td>-</td>
<td>2,722</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* In Q1 and Q2 2012, the company recorded no revenue

As in previous quarters, Nanobiotix revenue for Q4 2013 corresponds to an upfront payment received by the company within the framework of the licensing contract signed with PharmaEngine, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. The total upfront payment is €810,640, of which €46,351 is the pro rata amount for the period, and €185,030 is for the full year in 2013. The invoicing of services totalled €2,316 for the period. In total, revenues for Q4 2013 were €48,667, giving a total of €190,068 for 2013 which is fully in line with Company expectations.

As a reminder, PharmaEngine has committed to pay a maximum additional amount of US$56 million depending on the completion of different milestones and development of the clinical program.
Furthermore, Nanobiotix could receive double-digit royalties on net product sales in the Asian-Pacific region.

Public funding for research expenditures, which comprises a research tax credit, is not included in the revenues but is part of the Company’s operating revenues, released with the half and full year results.

2013 - A successful year in terms of clinical progress

As a reminder, the NanoXray pipeline progressed significantly over the past 12 months. Lead product NBTXR3 achieved clinical proof-of-concept, and the two other products of the pipeline, NBTX-IV and NBTX-TOPO, reached major preclinical milestones.

*Click on the following link to download the 2013 review of the NanoXray pipeline progress*

2013: significant progress for Nanobiotix

Nanobiotix and the ETPN partners at the Second Nano World Cancer Day

Within the framework of the World Cancer Day, Nanobiotix led the French element at the Nano World Cancer Day, European press conference, coordinated by the European Technology Platform on Nanomedicine (ETPN). The event occurred simultaneously in 13 countries within Europe and was an opportunity to highlight the present and future nanomedicine benefits and its range of applications against cancer, from diagnostic to therapeutic perspectives. As Vice-Chairman of the ETPN, Laurent Levy, CEO of Nanobiotix, took part in this conference, alongside recognized industrials among healthcare sector.

*For more information, click here*

Promising outlook for 2014

For Nanobiotix, 2014 will be a pivotal year for the company, during which we expect to achieve several significant milestones.

In terms of clinical development, Nanobiotix is expecting final results from the phase I study initiated in France on soft tissue sarcoma, the first intermediate results from the clinical study on head and neck cancers and anticipating the regulatory authorization for the start of the clinical trial in liver cancer within the framework of the NICE project. At the international level, Nanobiotix will be focused on its ambitious partnership policy with the initiation of two trials led by PharmaEngine in Asia and will be targeting the US territory [for development partners].

To support these key developments, the Nanobiotix management nominated Anne-Marie GRAFFIN (as a member) and Enno SPILLNER (as observer) to the Supervisory Board in January 2014. This is in addition to the recruitment of Philippe MAUBERNA as Chief Financial Officer and Sarah GAUBERT as Head of Communication and Public Affairs, in H2 2013 to strengthen the management team and the corporate governance.

We believe we are making major strides in our development and have the right team in place to fulfil our strategy and ambitions to make a significant impact in the field of nanomedicine.
About NANOBIOTIX - www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.


For more information, please contact:

Nanobiotix
Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com

Yucatan
Media relations (France)
Annie-Florence Loyer / Nadège Le Lezec
+33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59
afloyer@yucatan.fr

NewCap.
Financial communication and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53
lvdelouvrier@newcap.fr

College Hill
Media relations (Outside France)
Melanie Toyne Sewell / Donia Al Saffar
+44 (0) 207 457 2020
nanobiotix@collegehill.com

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2012 financial annual report of Nanobiotix (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.